adult Philadelphia chromosome/BCR-ABL1 positive acute lymphoblastic leukemia
Conditions
Interventions
experimental group:flumatinib combined with chemotherapy
Sponsors
Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Male or female patients aged 18-64 years; 2. Patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia; 3. Patients without serious heart disease or coronary heart disease history; 4. Patients with liver and kidney function suitable for chemotherapy: SGOT and SGPT should not exceed 2 times of the upper limit of normal; amylase and lipase in serum should not exceed 2 times of the upper limit of normal; total bilirubin in serum should not exceed 3 times of the upper limit of normal; 5. Patients willing to sign informed consent.
Exclusion criteria
Exclusion criteria: 1. History of other cancers, except basal cell carcinoma; 2. With contraindications of corticosteroids; 3. Diabetes which cannot be successfully controlled; 4. HIV and syphilis-infected patients; 5. Pregnancy or lactating women; 6. Patients previously received an organ transplantation; 7. Severe neurological or psychiatric history.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival;overall survival;minimal residual disease; | — |
Secondary
| Measure | Time frame |
|---|---|
| complete remission;safety;mutation rate of Abl kinase domain; | — |
Countries
China
Contacts
Public ContactJin Wang
Shanghai Institute of Hematology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine
Outcome results
None listed